Angiotensin blockade in late autosomal dominant polycystic kidney disease. - Wikidata - awgldk - TriplyDB

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

http://www.wikidata.org/entity/Q34836649

about

Interventions for preventing the progression of autosomal dominant polycystic kidney disease Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging The Treatment of Autosomal Dominant Polycystic Kidney Disease A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research.Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology Rationale, design and objectives of ARegPKD, a European ARPKD registry study Molecular pathways and therapies in autosomal-dominant polycystic kidney disease Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling.Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria.Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.Closeout of the HALT-PKD trials Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials.Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.Application of new acute kidney injury biomarkers in human randomized controlled trials.Hypokalemic Hypertension Leading to a Diagnosis of Autosomal Dominant Polycystic Kidney Disease.Heterotrimeric G protein signaling in polycystic kidney disease Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients An association between autosomal-dominant polycystic kidney disease and the risk of acute myocardial infarction in Asian population - results of a nationwide study New options in the treatment of autosomal dominant polycystic kidney disease.The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.Methodological issues in clinical trials of polycystic kidney disease: a focused review.Clinical Trials and a View Toward the Future of ADPKD.Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer.Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease Recent advances in autosomal-dominant polycystic kidney disease.Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.Clinical Manifestation and Management of ADPKD in Western Countries.Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.CTGF Is Expressed During Cystic Remodeling in the PKD/Mhm (cy/+) Rat Model for Autosomal-Dominant Polycystic Kidney Disease (ADPKD).Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.

P2860

Q24186484-ECCA4854-970A-4AD2-BC5D-934B01EBBE51 Q26795398-3027A489-03A1-4A44-841D-FA7A67FA032D Q26798115-F3CBDF04-9EA9-4CEA-8A0B-44E964413019 Q27313611-6B150D3B-54BD-44B4-B327-F741F455A981 Q28077060-44B8CE59-9590-4468-B0F9-521732893F76 Q30204911-8A77B121-5521-4966-9A12-C2E312C2AF1E Q34467747-F5F6C4FF-8F1A-45D8-A8F5-5F76B47FBA81 Q35026517-13F1A4CE-CBB6-4E88-A7B1-3643C5F39679 Q35176977-28B6881C-DDE6-42E2-986C-DC303516AB45 Q35578646-1A76585C-A7E0-42E2-81A9-8FF3B5516F1D Q35923732-5FEE7DA8-F84A-41F2-BA99-FCED577BDF76 Q35982717-7694CC85-15F7-45A6-AE89-1644C1A7507D Q36106884-D28320F2-3F9B-4114-962F-6ACA0E65FCF1 Q36385359-7D504927-3973-40A1-ACE9-43EC25F19A21 Q36520637-95CF4173-F6F6-4821-91D2-89A84F994C00 Q36618913-D63DE8CD-D18B-4888-ACFF-18BFFC84BAA3 Q36753925-0291514A-26B7-4CFE-B6E8-65E72AE5DC4C Q36909005-6EDD314E-0226-4373-8100-B6E9836D6B29 Q37104447-0A8A36B0-25DA-42AA-96B8-D2D26F1B0AB2 Q37139683-CC2E6737-2EBE-44E4-947E-597C161A637A Q37606169-5B5F7E2E-DC54-4563-AE1C-3B362C692469 Q37746000-1760789E-F578-40F8-933D-0F31820B0600 Q38356125-37A7A004-7565-47A0-BC4E-481861D1CF10 Q38419495-9F03FD52-26BF-4DCE-9263-B4A754B70667 Q38540557-39AC1600-6487-4DEC-A6F4-E519AB3B3AB1 Q38545232-981A4568-D5A6-46BA-A6DB-8B0D2BA12FFA Q38794129-D70C6F52-F611-43EB-8F3C-0710EDC53816 Q38812543-D890F38B-3B18-45E5-AF85-B9D9C22A13FE Q38911616-8CD743B6-AD3E-4951-B230-13D09A06DDAF Q38914739-2D839DF8-A36F-4D82-B3FE-9A0A75FE969D Q38935264-1524EC49-3E04-4989-830E-04860258C466 Q38960067-EA4108CE-BF67-4ECC-9405-7EB73CA392E3 Q39030254-AD28FF6E-F6C7-4C06-BC8E-C824FF9E87A5 Q40123527-DBB4DCBD-2651-470F-81EC-E06C0D218137 Q46239170-BF884144-3E68-4F55-9127-465050862645 Q47116963-55FA95CA-1E3E-4B56-921E-0CB4C6737DEE Q47202226-3F2E0004-CE49-41E2-8085-ED5990E9404A Q47616685-1656143D-0B6B-49B1-B72C-4296070D9EA1 Q47666190-FF4DD732-7FB3-487B-AEED-49A00F439C6E Q47742358-C9D468EE-D40C-4B91-A0BB-0F086197D653

P2860

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

http://www.wikidata.org/entity/Q34836649

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@ast

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@en

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@nl

type

label

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@ast

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@en

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@nl

prefLabel

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@ast

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@en

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@nl

P1433

Q34836649-D995E309-ADBE-40B4-BB16-C162F90839C1

P1476

Q34836649-C6B8359C-E7C5-435D-88F5-A0BFE3ADBD09

P2093

Q34836649-0A1DC84A-C1CB-4742-A717-02C62082BC49

Q34836649-0B12FA09-2271-459A-9B62-B40D2F16D38C

Q34836649-0C6D25E6-4DE7-40F6-8041-471FE6E5190A

Q34836649-125FD1C2-BE1E-419C-87A2-05380BDD1F69

Q34836649-29366E77-BAA5-4D63-A7C9-6F4AECB16116

Q34836649-2FFCACD5-F9CF-46B7-A410-FB186D7A992F

Q34836649-4BFBBC26-F144-4D9D-BE48-B2DDEF65F333

Q34836649-73D41A86-F9BC-41A4-9927-430B471FB4BE

Q34836649-74E50E3C-0321-44C3-B075-5B03C9733A2F

Q34836649-96C61508-95FF-4B32-A152-26BFF0284C15

P2860

Q34836649-1058124D-EB6F-4F5E-930C-3689C247D49B

Q34836649-19411354-03BD-4838-97A9-2FF7C5D9B716

Q34836649-1D9871A6-CDA7-46C2-A0EE-1221D5570EE2

Q34836649-2486B314-A760-490D-931A-A337323B3B1B

Q34836649-2A1D1B22-AF9E-45DD-9DDD-5579F39FCF28

Q34836649-42B2939B-CACA-4D57-BF23-AC415D4611A5

Q34836649-442BC210-6121-4B69-8ADD-0A75F955232A

Q34836649-4DBBA5FC-FF40-4844-98FD-61027D1E22D4

Q34836649-4FD20E47-A06E-4B6F-9A68-83547F2FDC39

Q34836649-4FEADC4E-6282-44AC-990A-9051BB3E0428

P304

Q34836649-DA93EFC1-0F3D-400C-B7C0-EA40551D3C32

P31

Q34836649-301E0E9F-5A19-4EEC-A4C2-0129C8CECBBB

P356

Q34836649-B4C470EF-07BC-4CA0-84E3-0BA9A2B9ADC1

P407

Q34836649-12A0E0ED-4B23-4FF6-B82E-D715CE03C53D

P433

Q34836649-F5D16CC4-C715-4E73-A441-EDE9A00F0F8D

P478

Q34836649-CF505B73-1FB2-4F14-B37C-F1520C54D59B

P50

Q34836649-75E4CB60-AE78-44B0-8242-66803BC5562B

P577

Q34836649-3FBB4A9C-078C-4041-A8C9-3DA0CB3D7E14

P698

Q34836649-7A75D487-9308-4F0C-8473-8A10915D66B7

P921

Q34836649-84979C95-5749-43DB-8607-042A48FD82D0

P932

Q34836649-C47A5BF4-BC1D-46DC-AC30-0D3D2CBC9C37

P356

P1433

The New England Journal of Medicine

P1476

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

@en

P2093

Arlene B Chapman

http://www.w3.org/2001/XMLSchema#string

Charity G Moore

http://www.w3.org/2001/XMLSchema#string

Dana C Miskulin

http://www.w3.org/2001/XMLSchema#string

Franz T Winklhofer

http://www.w3.org/2001/XMLSchema#string

Frederic F Rahbari-Oskoui

http://www.w3.org/2001/XMLSchema#string

Godela Brosnahan

http://www.w3.org/2001/XMLSchema#string

HALT-PKD Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Jared J Grantham

http://www.w3.org/2001/XMLSchema#string

Kaleab Z Abebe

http://www.w3.org/2001/XMLSchema#string

Marie C Hogan

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Shared parameter models for the joint analysis of longitudinal data and event times.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

The HALT polycystic kidney disease trials: design and implementation.

Clinical practice. Autosomal dominant polycystic kidney disease.

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Blood pressure in early autosomal dominant polycystic kidney disease.

P304

2267-2276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1402686

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Robert W Schrier

P577

2014-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25399731

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

4284824

http://www.w3.org/2001/XMLSchema#string